|
|
|
Fibromyalgia |
|
| Fibromyalgia treatments with up to 77% symptom relief. | |
| |
|
Rheumatoid Arthritis (RA) |
|
| Rheumatoid Arthritis treatments with up to 80% symptom relief. | |
|
| |
|
Osteoarthritis (OA) |
|
| Osteoarthritis Arthritis treatments with up to 78% symptom relief. | |
|
| |
|
Arthritis (Undiagnosed) |
|
| Find Relief from any form of Arthritis with an average of 75% symptom relief. | |
|
| |
|
A Simple Solution: Book and DVD If you wish to read more about Virgil and Helen, and the creation of Microdose Therapy, pick up Virgil's book 
Out of Order Click on the images above to learn more about this offer. |
Solution to Rheumatic Disease
Learn how the hormone cortisol subdues inflammation; discover the role cortisol plays in Microdose Therapy and learn about the Microdose Therapy program itself.
|
Solution (for laypersons) People with long-term, destructive inflammation must take extra of the body’s inflammation-controlling hormone cortisol in tablet form, stay off foods to which they are allergic, and take an antibiotic until well. Then, they must be taught to take cortisol tablets on the bad days and not on the good ones. In this way, they manually restore the cortisol pulse of the body’s inflammation control system that terminates short-term, beneficial inflammation and prevents it from becoming long-term, destructive inflammation. By taking cortisol as needed, cortisol over dosage is avoided. Patient education is essential. Microdose Therapytm is a 12-month, physician-supervised, patent-pending technology, one-time education program that teaches people to allow short-term, beneficial inflammation and terminate long-term, harmful inflammation by cortisol self-administration. It is a synergistic combination of clinical trial-proven technologies: two that limit inflammation initiation (allergies and occult infections) and one that terminates inflammation (cortisol self-administration). Once taught, patients may use cortisol self-administration the rest of their lives. Microdose Therapy works for diseases with long-term, destructive inflammation:
Solution (for scientists) The correction of the endocrine inflammation control system malfunction that allows short-term, beneficial inflammation to evolve into long-term, destructive inflammation is to teach people to take cortisol tablets to manually rebuild the pulse as needed. Cortisol taken at other times will likely create hypercortisonism (over dosage) with its tell-tale moon-face, weight gain, thinning of the skin, bleeding under the skin, weakening of the bones and cataracts. The scientific design of Microdose Therapy solves the renowned hypercortisonism and adrenal suppression problems of daily glucocorticoid therapy. Hypercortisonism is avoided in the scientific design of Microdose Therapy by limiting average cortisol content of the flare quenching regimens to be equal to or less than the safe limits of daily use defined in Table l. Hypercortisonism is inherent with daily cortisol administration. When administered in sufficient daily dosages to quench inflammation, hypercortisonism occurs. When the daily dosage is lowered to where hypercortisonism adverse reactions disappear, disease symptoms reappear. Table 1. Currently Estimated, Maximally Tolerated, Daily Doses for Long-term Hormonal Therapy in Rheumatoid Arthritis [Slocumb CH, Polley HF, Ward L. Diagnosis, treatment and prevention of hypercortisonism in patients with rheumatoid arthritis. Staff Meetings of the Mayo Clinic, 32(a): 227-238, 1957]
In practice, patients using Microdose Therapy average 3 mg prednisone per day and 12 mg of cortisol per day depending upon which glucocorticoid is used [Stenberg VI, Fiechtner JJ, Rice JR, Miller DR, Johnson LK. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. Int J Clin Pharm Res , 12(1): 11-18, 1992]. In accord with expectations for the data of Table l, no significant hypercortisonism adverse reactions have been observed in thousands of patients served. In a 1988 Medical World News editorial, Healey wrote “A low dose such as 7.5 mg prednisone per day is not cumulative and is thought to be useable indefinitely without producing osteoporosis or other serious adverse effects.” [Healey LA, Changing Therapy, Medical World News, December 12, 1988] Adrenal suppression is avoided in Microdose Therapy by teaching patients to take cortisol holidays. Empirically, patients average 3.3 disease flares per month [Stenberg VI, Fiechtner JJ, Rice JR, Miller DR, Johnson LK. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. Int J Clin Pharm Res , 12(1): 11-18, 1992]. With this knowledge, Microdose Therapy patients are taught to limit cortisol use to four 5-day flare-quenching cortisol regimens per month. This forces 33% cortisol holidays during which adrenals exercise cortisol production. Proof that adrenal suppression does not occur with this limitation is that patients average the same or less cortisol per month with passing years using Microdose Therapy [unpublished results]. Adrenal suppression occurs when cortisol is administered daily over prolonged periods. Initially, the added cortisol dosage adds to the daily adrenal production of cortisol. With time, the adrenals reduce cortisol production to compensate for the added cortisol, and adrenal atrophy occurs. Harris found that administering the physiological amount of prednisone daily to rheumatoid arthritis patients initially produced an 18% symptom improvement. Six months later, the symptom improvement disappeared presumably because of adrenal suppression [Harris ED, Low dose prednisone therapy in rheumatoid arthritis: a double blind study, Journal of Rheumatology, 10, 713-721, 1983]. Solution (for physicians) Microdose Therapytm is a 12-month, physician-supervised, education program that teaches patients to allow short-term, beneficial inflammation and terminate long-term, harmful inflammation by cortisol self-administration. Its protocol is a synergistic combination of clinical trial-proven technologies: two that limit inflammation initiation (allergies and occult infections) and one that terminates inflammation (cortisol self-administration). Each technology has been tested by clinical trials [Stenberg et al. Int. J. Clin. Pharm. Res., 12(1), 11-18, 1992; Panush et al. Food-induced (allergenic) arthritis. Arth and Rheum 29: 220-226, 1986; Kloppenberg et al. Clin Exper Rheum (Supplement 8): S113-115, 1993]. By teaching patients to take cortisol on the bad days and not on the good ones, they use so little that they avoid cortisol side effects. The required 33% cortisol holidays avoid adrenal suppression. For convenience for physicians, the Helen Foundation provides the protocol, recommend cortisol dosages, and provide the patient education required. Physicians diagnose, perform the essential medical exams and monitor for adverse events. Cortisol is indicated for gastrointestinal diseases: “Indications: Endocrine Disorders, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, Gastrointestinal Diseases and Miscellaneous.” [Physician Desk Reference 2001 edition, pages 1940-1941, on cortisol (hydrocortisone)] Microdose Therapy cortisol use is consistent with FDA recommendations: ”Dosage and Administration: DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT. The initial dosage varies from 20 to 240 mg a day depending on the disease being treated. In less severe diseases doses lower than 20 mg may suffice, while in severe diseases doses higher than 240 mg may be required. The initial dosage should be maintained or adjusted until the patient’s response is satisfactory. If satisfactory clinical response does not occur after a reasonable period of time, discontinue hydrocortisone and transfer the patient to other therapy. After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response. Patient should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily.” [Physician Desk Reference 2001 edition, pages 1940-1941, on cortisol (hydrocortisone)] Cortisol self-administration for cortisol-responding conditions is like insulin self-administration for diabetes. In thousands of patients, the Helen Foundation has found that 83% of patients enrolled in Microdose Therapy achieve an average of 78% symptom relief. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Home | Diseases & Conditions | Contact Us | Video | Donations